BIOSPECIMENS AND XENOGRAFT

生物样本和异种移植物

基本信息

批准号：
10220873
负责人：
JEROME RITZ
金额：
$ 2.06万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-19 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10220873
关键词：
Biological Assay Bone Marrow Cells Clinical Clinical Research Protocols Collaborations Collection Core Facility Cryopreservation Cytogenetics DNA DNA sequencing Databases Development Diagnosis Enrollment Goals Hematologic Neoplasms Immunology Immunophenotyping Infrastructure Laboratories Menin Mission Molecular Mononuclear Myeloid Leukemia Myeloproliferative disease Pathologic Patients Plasma Play Protocols documentation Reagent Reproduction spores Research Research Personnel Research Project Grants Resources Role SYK gene Sampling Specimen Spliceosomes Testing Tissue Banks Transplant Recipients Transplantation Work Xenograft Model Xenograft procedure experience experimental study falls improved in vitro Assay in vivo Model leukemia molecular marker novel novel therapeutics open source patient derived xenograft model preclinical trial preservation prospective repository success transcriptome sequencing web site

项目摘要

Abstract The major goals of Core 2 are to provide the SPORE with the infrastructure and professional expertise needed to bank, characterize and distribute primary specimens and patient-derived xenograft (PDX) models. These will be prospectively collected from patients through established protocols developed by the Administrative Core (Core 1), assayed using novel molecular biomarker tests by the Translational Core (Core 3) and serve as essential reagents for each of the Research Projects. Core 2 will be jointly directed by Drs. Jerome Ritz and Dr. David Weinstock. Dr. Jerome Ritz has worked in leukemia and transplant research at DFCI for more than 30 years and has extensive experience in cell collection, processing, cryopreservation, flow cytometric analysis and purification, transplant immunology, and database development. Dr. Ritz is currently the Executive Director of the Connell O'Reilly Cell Manipulation Core Facility (CMCF) at DFCI. The Pasquarello Tissue Bank for Hematologic Malignancies was established as a unit of the CMCF in 2001 and will be responsible for processing, banking and distribution of primary myeloid malignancies for this SPORE. This resource has already acquired over 4,000 bone marrow samples from over 1,500 unique patients with myeloid leukemias that are available for use by SPORE investigators. Dr. Weinstock directs the DFCI Hematologic Malignancy PDX repository, which already contains >300 transplantable PDX models that have been viably cryopreserved and are available for SPORE investigators. These are fully characterized by whole transcriptome sequencing, DNA sequencing, immunophenotyping and other molecular assays. Existing patient samples and PDX lines have already been shared with Project investigators. Moreover, the Core has extensive experience with utilizing primary patient specimens for in vitro assays and PDX models for in vivo pre-clinical trials of novel therapies. Aim 1 of the Core is to acquire primary samples from patients with myeloid malignancies enrolled in clinical research protocols and to isolate and preserve viable mononuclear cells, DNA and plasma. Aim 2 is to establish, characterize, and distribute xenograft models of myeloid malignancies and facilitate pre-clinical trials in collaboration with the Projects. Aim 3 is to maintain annotated databases containing pathologic, cytogenetic and molecular information for clinical samples and xenografts obtained from patients with myeloid malignancies. By successfully pursuing these aims, the Core plays an essential role in the success of the SPORE and its collective efforts to improve the diagnosis and treatment of patients with myeloid neoplasms.

抽象的 Core 2 的主要目标是为 SPORE 提供所需的基础设施和专业知识储存、表征和分发主要标本和患者来源的异种移植 (PDX) 模型。这些将通过行政部门制定的既定方案前瞻性地从患者身上收集核心（核心 1），通过转化核心（核心 3）使用新型分子生物标志物测试进行测定，并作为每个研究项目的必需试剂。 Core 2 将由 Drs 联合指导。杰罗姆·里兹和大卫·温斯托克博士。 Jerome Ritz 博士在 DFCI 从事白血病和移植研究工作超过 30年，在细胞采集、处理、冷冻保存、流式细胞分析方面拥有丰富的经验和纯化、移植免疫学和数据库开发。 Ritz 博士现任执行官 DFCI 康奈尔·奥莱利细胞操作核心设施 (CMCF) 主任。帕斯夸雷洛组织库血液恶性肿瘤中心于 2001 年作为 CMCF 的一个单位成立，负责该孢子的原发性骨髓恶性肿瘤的处理、储存和分配。该资源有已经从 1,500 多名独特的髓性白血病患者采集了 4,000 多个骨髓样本可供 SPORE 调查员使用。 Weinstock 博士指导 DFCI 血液恶性肿瘤 PDX 存储库，已包含超过 300 个可移植的 PDX 模型，并且已有效冷冻保存可供 SPORE 调查员使用。这些通过全转录组测序得到了充分的表征， DNA 测序、免疫表型分析和其他分子检测。现有患者样本和 PDX 线已与项目调查人员共享。此外，核心在以下方面拥有丰富的经验：利用主要患者标本进行体外测定，并利用 PDX 模型进行新型药物的体内临床前试验疗法。核心目标 1 是从入组的骨髓恶性肿瘤患者中获取主要样本临床研究方案以及分离和保存活的单核细胞、DNA 和血浆。目标 2 是建立、表征和分发骨髓恶性肿瘤的异种移植模型并促进临床前试验与项目合作。目标 3 是维护包含病理学、细胞遗传学的注释数据库从髓系患者获得的临床样本和异种移植物的分子信息恶性肿瘤。通过成功地实现这些目标，核心在项目的成功中发挥着至关重要的作用。 SPORE 及其为改善骨髓肿瘤患者的诊断和治疗所做的集体努力。